Akebia Therapeutics, Inc.
AKBA
$1.44
$0.021.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 236.20M | 225.07M | 203.73M | 184.91M | 160.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.20M | 225.07M | 203.73M | 184.91M | 160.18M |
| Cost of Revenue | 40.09M | 37.28M | 32.92M | 30.51M | 25.06M |
| Gross Profit | 196.11M | 187.79M | 170.81M | 154.40M | 135.12M |
| SG&A Expenses | 107.48M | 109.07M | 106.49M | 106.85M | 106.55M |
| Depreciation & Amortization | -- | 9.01M | 18.02M | 27.03M | 36.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 209.93M | 202.86M | 198.47M | 202.06M | 205.30M |
| Operating Income | 26.27M | 22.22M | 5.26M | -17.15M | -45.12M |
| Income Before Tax | -3.72M | -15.29M | -36.48M | -45.31M | -69.41M |
| Income Tax Expenses | 1.62M | 615.00K | -- | -- | -- |
| Earnings from Continuing Operations | -5.35 | -15.91 | -36.48 | -45.31 | -69.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.35M | -15.91M | -36.48M | -45.31M | -69.41M |
| EBIT | 26.27M | 22.22M | 5.26M | -17.15M | -45.12M |
| EBITDA | 27.54M | 32.51M | 24.61M | 11.29M | -7.61M |
| EPS Basic | -0.02 | -0.08 | -0.17 | -0.21 | -0.33 |
| Normalized Basic EPS | 0.00 | -0.03 | -0.10 | -0.12 | -0.19 |
| EPS Diluted | -0.02 | -0.08 | -0.18 | -0.22 | -0.34 |
| Normalized Diluted EPS | 0.00 | -0.03 | -0.10 | -0.12 | -0.19 |
| Average Basic Shares Outstanding | 1.03B | 981.55M | 927.11M | 874.25M | 843.71M |
| Average Diluted Shares Outstanding | 1.05B | 1.01B | 941.75M | 880.36M | 843.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |